Lin BioScience Inc. (6696.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan
Lin BioScience Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Gross profit | -20.21 m TWD | – |
| Operating income | -1.46 bn TWD | -2.86 bn TWD |
| EBIT | -1.46 bn TWD | -2.64 bn TWD |
| Net income | -744.27 m TWD | -1.36 bn TWD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Lin BioScience Inc.
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an first-in-class anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. Lin BioScience, Inc. is headquartered in Taipei, Taiwan.
More stocks
- Liechtensteinische Landesbank AG (LLBN.SW)
- Aixtron (AIXA.DE)
- Kumba Iron Ore Ltd (KIO.JO)
- GDS Holdings Ltd (GDS)
- Joulwatt Technology Co. Ltd. A (688141.SS)
- Cosmo Energy Holdings Co Ltd (5021.T)
- Fujian Wanchen Biotechnology Co. Ltd (300972.SZ)
- JOYY Inc (JOYY)
- Kontoor Brands, Inc. (KTB)
- Athens International Airport SA (AIA.AT)
- Grinm Advanced Materials Co Ltd (600206.SS)
- SCHOTT Pharma AG & Co KgaA (1SXP.DE)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.